| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/12/2024 | 22:10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 20/12/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 10/12/2024 | 20:27 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 05/12/2024 | 15:00 | GlobeNewswire Inc. | Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 25/11/2024 | 23:00 | GlobeNewswire Inc. | Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 22/11/2024 | 23:28 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 21/11/2024 | 23:10 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 19/11/2024 | 15:00 | GlobeNewswire Inc. | Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 15/11/2024 | 22:05 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 14/11/2024 | 22:25 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 01/11/2024 | 14:00 | GlobeNewswire Inc. | Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 09/10/2024 | 22:10 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 26/09/2024 | 23:10 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Announces management changes. | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 20/09/2024 | 15:00 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 06/09/2024 | 23:00 | GlobeNewswire Inc. | Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 06/09/2024 | 22:30 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 06/09/2024 | 21:46 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 05/09/2024 | 15:00 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 22/08/2024 | 22:41 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 01/07/2024 | 14:00 | GlobeNewswire Inc. | Lifecore Biomedical Announces Cooperation Agreement with 22NW | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 30/05/2024 | 22:00 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 14/05/2024 | 22:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 16/04/2024 | 13:00 | GlobeNewswire Inc. | Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 10/04/2024 | 14:00 | GlobeNewswire Inc. | Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 09/04/2024 | 14:00 | GlobeNewswire Inc. | Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 14/11/2023 | 22:30 | GlobeNewswire Inc. | Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 07/11/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 23/10/2023 | 14:30 | GlobeNewswire Inc. | Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 27/09/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 01/09/2023 | 22:15 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:QLGN | Qualigen Therapeutics Inc |